Thomas Muster

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium.

Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium.

Journal: Frontiers in immunology

Published: January 30, 2025

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity.

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity.

Journal: NPJ vaccines

Published: December 20, 2023

Prophylactic Protection Against Respiratory Viruses Conferred by a Prototype Live Attenuated Influenza Virus Vaccine.

Prophylactic Protection Against Respiratory Viruses Conferred by a Prototype Live Attenuated Influenza Virus Vaccine.

Journal: Research square

Published: August 17, 2021

Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1.

Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1.

Journal: Scientific reports

Published: June 28, 2021

Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.

Influenza virus vector iNS1 expressing bovine papillomavirus 1 (BPV1) antigens efficiently induces tumour regression in equine sarcoid patients.

Journal: PloS one

Published: May 28, 2021

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.

Journal: bioRxiv : the preprint server for biology

Published: May 05, 2021

Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.

Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.

Journal: Vaccine

Published: December 17, 2018

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Correction: Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Journal: PloS one

Published: November 13, 2015

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Attenuated Recombinant Influenza A Virus Expressing HPV16 E6 and E7 as a Novel Therapeutic Vaccine Approach.

Journal: PloS one

Published: April 22, 2015

A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice.

A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice.

Journal: Archives of virology

Published: March 06, 2015

Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography.

Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography.

Journal: Vaccine

Published: November 27, 2013

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.

Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.

Journal: Vaccine

Published: October 20, 2013

Showing 1-12 of 18

Last Updated: 09/26/2026